JPWO2023176863A5 - - Google Patents
Info
- Publication number
- JPWO2023176863A5 JPWO2023176863A5 JP2024508205A JP2024508205A JPWO2023176863A5 JP WO2023176863 A5 JPWO2023176863 A5 JP WO2023176863A5 JP 2024508205 A JP2024508205 A JP 2024508205A JP 2024508205 A JP2024508205 A JP 2024508205A JP WO2023176863 A5 JPWO2023176863 A5 JP WO2023176863A5
- Authority
- JP
- Japan
- Prior art keywords
- rna
- nucleoside
- ome
- oligonucleotide
- ome rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022041865 | 2022-03-16 | ||
| PCT/JP2023/009974 WO2023176863A1 (ja) | 2022-03-16 | 2023-03-15 | ＲＮＡｉ活性を有する化学修飾オリゴヌクレオチド |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2023176863A1 JPWO2023176863A1 (https=) | 2023-09-21 |
| JPWO2023176863A5 true JPWO2023176863A5 (https=) | 2026-03-24 |
Family
ID=88023882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024508205A Pending JPWO2023176863A1 (https=) | 2022-03-16 | 2023-03-15 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250188477A1 (https=) |
| EP (1) | EP4495241A1 (https=) |
| JP (1) | JPWO2023176863A1 (https=) |
| KR (1) | KR20240154682A (https=) |
| CN (1) | CN118871585A (https=) |
| TW (1) | TW202400786A (https=) |
| WO (1) | WO2023176863A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12454693B1 (en) * | 2024-09-27 | 2025-10-28 | Dexcel Pharma Technologies Ltd. | Nucleic acids for inhibiting expression of transferrin receptor 2 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7119184B2 (en) | 1991-08-12 | 2006-10-10 | Isis Pharmaceuticals, Inc. | Oligonucleotides having A-DNA form and B-DNA form conformational geometry |
| JPH0787982A (ja) | 1993-01-29 | 1995-04-04 | Sankyo Co Ltd | 修飾オリゴデオキシリボヌクレオチド |
| US6096881A (en) | 1997-05-30 | 2000-08-01 | Hybridon, Inc. | Sulfur transfer reagents for oligonucleotide synthesis |
| JP4236812B2 (ja) | 1997-09-12 | 2009-03-11 | エクシコン エ／エス | オリゴヌクレオチド類似体 |
| ES2234563T5 (es) | 1999-02-12 | 2018-01-17 | Daiichi Sankyo Company, Limited | Nuevos análogos de nucleósidos y oligonucleótidos |
| US6261840B1 (en) | 2000-01-18 | 2001-07-17 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
| WO2009073809A2 (en) | 2007-12-04 | 2009-06-11 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| US20110196141A1 (en) | 2009-09-07 | 2011-08-11 | Council Of Scientific & Industrial Research | Locked and unlocked 2'-o phosphoramidite nucleosides, process of preparation thereof and oligomers comprising the nucleosides |
| WO2011072082A2 (en) | 2009-12-09 | 2011-06-16 | Nitto Denko Corporation | Modulation of hsp47 expression |
| WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
| WO2012074038A1 (ja) | 2010-12-02 | 2012-06-07 | 第一三共株式会社 | 修飾１本鎖ポリヌクレオチド |
| EP2723861A4 (en) | 2011-06-21 | 2014-12-10 | Alnylam Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR INHIBITING HEPCIDINE ANTIMICROBIAL PEPTIDE (HAMP) OR THE ASSOCIATED GENE EXPRESSION |
| SI3366775T2 (sl) | 2011-11-18 | 2025-12-31 | Alnylam Pharmaceuticals, Inc. | Modificirana sredstva RNAI |
| EP3730618A1 (en) | 2011-11-18 | 2020-10-28 | Alnylam Pharmaceuticals, Inc. | Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases |
| CN104837996A (zh) | 2012-11-15 | 2015-08-12 | 罗氏创新中心哥本哈根有限公司 | 抗apob反义缀合物化合物 |
| WO2014109384A1 (ja) | 2013-01-10 | 2014-07-17 | 塩野義製薬株式会社 | 架橋型核酸誘導体の製造方法 |
| DK2992098T3 (da) | 2013-05-01 | 2019-06-17 | Ionis Pharmaceuticals Inc | Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression |
| WO2015006740A2 (en) | 2013-07-11 | 2015-01-15 | Alnylam Pharmaceuticals, Inc. | Oligonucleotide-ligand conjugates and process for their preparation |
| JP6482475B2 (ja) | 2014-01-07 | 2019-03-13 | レナセラピューティクス株式会社 | アンチセンスオリゴヌクレオチド及び糖誘導体を含む二本鎖オリゴヌクレオチド |
| IL316808A (en) | 2014-08-20 | 2025-01-01 | Alnylam Pharmaceuticals Inc | Modified double-stranded RNA materials and their uses |
| US20170034685A1 (en) | 2015-07-27 | 2017-02-02 | Qualcomm Incorporated | Lte-d2d discovery in the unlicensed band |
| KR102222186B1 (ko) | 2015-08-13 | 2021-03-03 | 머크 샤프 앤드 돔 코포레이션 | Sting 효능제로서 시클릭 디-뉴클레오티드 화합물 |
| BR112018003910B1 (pt) | 2015-11-16 | 2022-03-22 | F. Hoffmann-La Roche Ag | Derivado de fosforamidita galnac, processo para a preparação de um derivado de fosforamidita galnac de fórmula i e uso dos derivados de fosforamidita galnac de fórmula i |
| AU2017213404A1 (en) | 2016-01-29 | 2018-09-20 | Kyowa Kirin Co., Ltd. | Nucleic acid conjugate |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| KR102398295B1 (ko) | 2018-03-09 | 2022-05-17 | 다이이찌 산쿄 가부시키가이샤 | 당원병 Ia형 치료약 |
| JP2021520355A (ja) * | 2018-04-13 | 2021-08-19 | ディセルナ ファーマシューティカルズ インコーポレイテッド | Ｔｍ上昇ヌクレオチドで修飾された二本鎖核酸阻害剤分子 |
| KR20220062517A (ko) * | 2019-08-15 | 2022-05-17 | 아이오니스 파마수티컬즈, 인코포레이티드 | 결합 변형된 올리고머 화합물 및 이의 용도 |
| IL291251B1 (en) | 2019-09-10 | 2026-02-01 | Daiichi Sankyo Co Ltd | Oligonucleotide-galnac conjugate for targeted delivery to the liver and method for its production |
| KR20220148241A (ko) * | 2020-02-28 | 2022-11-04 | 알리고스 테라퓨틱스 인코포레이티드 | Pd-l1을 표적화하기 위한 방법 및 조성물 |
-
2023
- 2023-03-15 US US18/846,465 patent/US20250188477A1/en active Pending
- 2023-03-15 JP JP2024508205A patent/JPWO2023176863A1/ja active Pending
- 2023-03-15 KR KR1020247034185A patent/KR20240154682A/ko active Pending
- 2023-03-15 TW TW112109504A patent/TW202400786A/zh unknown
- 2023-03-15 EP EP23770816.9A patent/EP4495241A1/en active Pending
- 2023-03-15 WO PCT/JP2023/009974 patent/WO2023176863A1/ja not_active Ceased
- 2023-03-15 CN CN202380027810.3A patent/CN118871585A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021512629A5 (https=) | ||
| Teng et al. | G-quadruplex DNA: a novel target for drug design | |
| JP2018528781A5 (https=) | ||
| Obika et al. | 2′-O, 4′-C-Methylene bridged nucleic acid (2′, 4′-BNA): synthesis and triplex-forming properties | |
| JP2018088924A5 (https=) | ||
| JP2018199700A5 (https=) | ||
| EA015570B1 (ru) | Фармацевтическая композиция | |
| JP6924496B2 (ja) | ワンステップ逆転写テンプレートスイッチｐｃｒ | |
| WO2009093384A1 (ja) | ポリヌクレオチド及びポリヌクレオチド類似体並びにこれらを用いた遺伝子発現制御方法 | |
| JP2006508688A (ja) | ２’−置換核酸のインビトロ選択のための方法 | |
| JP5582580B2 (ja) | Ｈｍｇｂ１結合核酸分子およびその用途 | |
| WO2019182037A1 (ja) | 毒性が低減されたアンチセンスオリゴヌクレオチド | |
| JP2024515576A (ja) | 修飾ヌクレオシド | |
| Kumar et al. | Synthesis and biophysical properties of C5-functionalized LNA (locked nucleic acid) | |
| JPWO2023176863A5 (https=) | ||
| Wan et al. | Hybrid chemistry. Part 4: Discovery of etravirine–VRX-480773 hybrids as potent HIV-1 non-nucleoside reverse transcriptase inhibitors | |
| IL311294A (en) | Oligonucleotides comprising modified nucleosides | |
| JP2009502138A5 (https=) | ||
| JP6006814B2 (ja) | 核酸増幅用プライマーの設計方法、核酸増幅用プライマーの製造方法、核酸増幅用プライマー、プライマーセット、および核酸の増幅方法 | |
| JP4887500B2 (ja) | ヌクレオシド類似体またはその塩 | |
| AU2024353921A1 (en) | Novel sirna constructs, therapeutics, and modifications | |
| US20090143319A1 (en) | Transcription factor decoy | |
| Srivastava et al. | Achiral, acyclic nucleic acids: synthesis and biophysical studies of a possible prebiotic polymer | |
| CN116913417B (zh) | 一种dna结合小分子高通量筛选及表征方法 | |
| JP7338838B2 (ja) | 配列解析方法 |